Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by walkingredon Nov 15, 2016 2:04pm
282 Views
Post# 25464079

RE:RE:RE:IPF read out in a couple of days!

RE:RE:RE:IPF read out in a couple of days!Thank you Sah1,

Yes it's pretty incredible when I hear him talk...

One thing he did mention.... his father's readouts will be available in Mid January...

Now, I don't know if that's just something like they're gonna give him a prepared package for his own self, or if it refers to when we'll all hear about that group specifically... IDK

Whatever the case.  His  IPF condition has not progressed, and seems to have regressed.  Which is pretty huge.

He's also been signed on for continuation of the trial, which has made everyone really happy as he will have access to the doses at no cost, as long as the study is open.  Prety amazing there too.

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse